These results fully demonstrated that anti-PD1 therapy was more sensitive in a tumor microenvironment with CD8+ T cell enrichment, decreased immunosuppressive cells, and elevated PD-L1 on the tumor cell surface. Here, CD8A is linked to neoplasm.